CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing a drug delivery system that can effectively transport therapeutic agents across the blood-brain barrier for treating brain cancer. It aims to enhance drug efficacy while minimizing side effects by utilizing a patented technology that safely opens the barrier temporarily.
The partners wish to build a long term European, Industry-Academia consortium, to work on the problem of delivering therapeutic agents, e.g. for brain cancer, across the blood-brain barrier (BBB) at the efficacious dose.
Current treatment options for brain cancer are limited with patients having a poor prognosis.
One of the major hurdles is the BBB which prevents effective doses of drugs reaching the site of disease.
There is thus a major need for technologies that can successfully overcome such…
TECHNOLOGIKO EKPAIDEFTIKO IDRYMA ATHINAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Pharmidex Pharmaceutical Services Limited
United Kingdom, London
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, Brighton
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
